New hope for tough blood cancers: targeted pill shows promise in advanced leukemia
NCT ID NCT01589302
First seen Apr 21, 2026 · Last updated May 18, 2026 · Updated 4 times
Summary
This study tests a daily pill called ibrutinib in 154 people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL) that has come back or stopped responding to other treatments. The goal is to see how well the drug controls the cancer for at least two years. Participants take ibrutinib alone, and researchers track how long they live without the disease getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Medical Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.